STK15 rs2273535 polymorphism and cancer risk: A meta-analysis of 74,896 subjects
A partir d'une revue systématique de la littérature (52 études, 34 057 cas et 40 839 témoins), cette méta-analyse fait le point sur l'association entre un polymorphisme du gène STK15 et le risque de cancer, notamment en population asiatique
Background: It has been suggested that the serine/threonine kinase 15 (STK15) T91A rs2273535 polymorphism is associated with susceptibility to cancer. However, the results are conflicting. We performed this meta-analysis to derive a more precise estimation of the relationship. Methods: PubMed was searched to select studies. Case–control studies containing available genotype frequencies of the STK15 rs2273535 polymorphism were chosen, and the odds ratio (OR) with its 95% confidence interval (CI) was utilized to assess the strength of association. Results: 52 studies – including 34,057 cases and 40,839 controls – were identified. A significant effect of the STK15 rs2273535 polymorphism on cancer risk was found (AA vs. TT: OR = 1.13, 95%CI = 1.01–1.26, Pheterogeneity < 0.001; AA vs. TA/TT: OR = 1.12, 95%CI = 1.02–1.22, Pheterogeneity < 0.001; TA/AA vs. TT: OR = 1.06, 95%CI = 1.01–1.12, Pheterogeneity < 0.001). Stratified analysis by cancer type revealed that the STK rs2273535 polymorphism may contribute to the risk of breast cancer (AA vs. TT: OR = 1.21, 95%CI = 1.01–1.44, Pheterogeneity = 0.002), colorectal cancer (AA vs. TA/TT: OR = 1.24, 95%CI = 1.05–1.47, Pheterogeneity = 0.124), and esophageal cancer (AA vs. TA/TT: OR = 1.19, 95%CI = 1.02–1.39, Pheterogeneity = 0.148). Further subgroup analysis by ethnicity indicated that there was a statistically increased cancer risk in Asians (AA vs. TA/TT: OR = 1.20, 95%CI = 1.05–1.37, Pheterogeneity = 0.004). Conclusion: This meta-analysis suggests that the STK15 rs2273535 polymorphism is a candidate gene polymorphism for cancer susceptibility, especially in Asian populations.